0. DOCID:30247 SCORE: 0.00256592957518748
DOCNO: 16139958
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Apoptosis
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: physiopathology
QUALIFIER: physiology
AUTHOR: Ze-Jun Liu ZJ
AUTHOR: Xin Lu X
AUTHOR: Shan Zhong S
AFFILIATION: Laboratory of International Cooperation, Southwest Hospital, Third Military Medical University, Chongqing 400038, PRC. a65424208@cta.cq.cn
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Biochimica et biophysica acta.
COUNTRY: Netherlands
TITLE: ASPP--Apoptotic specific regulator of p53.
PUBDATE: 20050901
The p53 protein is one of the best-known tumor suppressors. The recently identified ASPP family (apoptosis-stimulating protein of p53) can interfere with the working of p53. Three members of ASPP family are proved to be apoptotic specific regulators of p53. The discovery of ASPP family may answer such questions as "how cells choose to die". Understanding the ASPP status in human cancer will allow us to develop better strategies to treat cancer.


1. DOCID:29442 SCORE: 0.00248915953012363
DOCNO: 12635085
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: Maureen F Zakowski MF
AFFILIATION: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Pathology of small cell carcinoma of the lung.
PUBDATE: 20030201
Small cell carcinoma of the lung is one of the major subtypes of primary lung cancer. It is a highly aggressive lethal neuroendocrine carcinoma. It is closely related to other neuroendocrine carcinomas of the lung, including carcinoid, atypical carcinoid, and large cell neuroendocrine carcinoma. This article discusses the classification of small cell carcinoma of the lung, identifies its cytologic and histologic characteristics, and places it in context with the other neuroendocrine carcinomas of the lung.


2. DOCID:29456 SCORE: 0.00248915951017022
DOCNO: 16425560
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: physiopathology
QUALIFIER: radiation effects
QUALIFIER: etiology
QUALIFIER: physiopathology
QUALIFIER: radiotherapy
QUALIFIER: etiology
QUALIFIER: pathology
QUALIFIER: pathology
QUALIFIER: radiation effects
QUALIFIER: adverse effects
AUTHOR: Wai Yip Stephen Lau WY
AUTHOR: Chun Kuen Chow CK
AFFILIATION: Division of Otorhinolaryngology, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of otology, rhinology, and laryngology.
COUNTRY: United States
TITLE: Radiation-induced petrous internal carotid artery aneurysm.
PUBDATE: 20051201
Iatrogenic internal carotid artery aneurysm is a rare complication of irradiation. There are few reported cases in the literature. A case of radiation-induced petrous internal carotid artery aneurysm in a patient with nasopharyngeal cancer treated with radiotherapy is reported. The approach to managing such an aneurysm is discussed.


3. DOCID:29853 SCORE: 0.00243890358567412
DOCNO: 16355210
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Peter Carmeliet P
AFFILIATION: Center of Transgene Technology and Gene Therapy, University of Leuven, Flanders Interuniversity Institute for Biotechnology (VIB), B-3000 Leuven, Belgium. peter.carmeliet@med.kuleuven.be.
PUBTYPE: Journal Article
JOURNALTITLE: Nature.
COUNTRY: England
TITLE: Angiogenesis in life, disease and medicine.
PUBDATE: 20051201
The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair. An imbalance in this process contributes to numerous malignant, inflammatory, ischaemic, infectious and immune disorders. Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness. Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.


4. DOCID:30583 SCORE: 0.00243888742240874
DOCNO: 16308096
OWNER: NLM
STATUS: In-Data-Review
QUALIFIER: pathology
QUALIFIER: trends
QUALIFIER: pathology
QUALIFIER: surgery
AUTHOR: William Chesnut Dooley WC
AFFILIATION: Oklahoma University Breast Institute, Cade Cancer Center, Oklahoma City, OK 73104, USA. william-dooley@ouhsc.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Clinics in laboratory medicine.
COUNTRY: United States
TITLE: The future prospect: ductoscopy-directed brushing and biopsy.
PUBDATE: 20051201
The intraductal approach to breast cancer and premalignant lesions has now developed to yield substantial cytologic samples of exfoliated cells. Standard cytology is still inadequate in sensitivity and specificity to accurately interpret the majority of samples. As techniques evolve using ductoscopic biopsy and molecular marker panels to increase accuracy of cytologic interpretation, these tools will be able to unravel the breast carcinogenesis pathways. They will also offer considerable benefit in screening for premalignant changes and developing effective chemoprevention strategies.


5. DOCID:30585 SCORE: 0.00243888698147658
DOCNO: 16408163
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Jerome E Tanner JE
AFFILIATION: TanTec Biosystems Inc., 11 Des Arbres, Dollard-Des-Ormeaux, Montreal, Quebec, Canada, H9G 3C2, jetanner@tantecbiosystems.com.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer metastasis reviews.
COUNTRY: Netherlands
TITLE: Designing antibodies for oncology.
PUBDATE: 20051201
The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par or superior to conventional drug therapies. This review outlines the various immunoglobulin design strategies currently available, techniques used to reduce Ig antigenicity and toxicity, and points to consider during the manufacture of antibodies for use in clinical oncology.


6. DOCID:31304 SCORE: 0.00227215837287253
DOCNO: 15046388
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: Prajnan Das P
AUTHOR: Irving Kaplan I
AFFILIATION: Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncology (Williston Park, N.Y.)
COUNTRY: United States
TITLE: The role of PC-SPES, selenium, and vitamin E in prostate cancer.
PUBDATE: 20020301
Prostate cancer patients commonly use complementary and alternative medications. There has been growing interest in recent years in the role of the herbal medication PC-SPES and the essential nutrients selenium and vitamin E in the prevention and treatment of prostate cancer. This article reviews the preclinical and clinical studies of these therapies. It is critical that health-care professionals be aware of the potential role and side effects of these widely used complementary and alternative therapies.


7. DOCID:30389 SCORE: 0.00221328160247028
DOCNO: 14976268
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: therapy
QUALIFIER: complications
AUTHOR: C Palmieri C
AUTHOR: D M Vigushin DM
AUTHOR: T J Peters TJ
AFFILIATION: Department of Cancer Medicine, Faculty of Medicine, Imperial College London, UK. c.palmieri@imperial.ac.uk
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: QJM : monthly journal of the Association of Physicians.
COUNTRY: England
TITLE: Managing malignant disease in patients with porphyria.
PUBDATE: 20040301
Certain types of porphyria have an increased incidence of malignant disease. In addition, patients with all forms of porphyria may develop malignant disease as a 'normal life event'. The investigation and treatment of porphyric patients with malignant disease requires specific precautions to minimize the risk of an acute porphyric attack, and to ensure optimum treatment of the malignancy. We briefly review the biochemical basis, clinical features and current management of porphyria in cancer patients.


8. DOCID:30230 SCORE: 0.00218738959477144
DOCNO: 16268939
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Models, Biological
QUALIFIER: etiology
AUTHOR: Kenny S Crump KS
AUTHOR: Ravi P Subramaniam RP
AUTHOR: Cynthia B Van Landingham CB
AFFILIATION: Environ Corporation, USA. kcrump@environcorp.com
PUBTYPE: Journal Article
JOURNALTITLE: Risk analysis : an official publication of the Society for Risk Analysis.
COUNTRY: United States
TITLE: A numerical solution to the nonhomogeneous two-stage MVK model of cancer.
PUBDATE: 20050801
In this article, we describe a straightforward method for solving the probability of at least one malignant cell by time t, and the associated hazard function, in the general (i.e., nonhomogeneous) two-stage Moolgavkar-Venzon-Knudson (MVK) model of cancer. The method consists of solving four coupled ordinary differential equations derived from the Kolmogorov backward equations for this process. The relationship of this method to previously proposed solutions is discussed.


9. DOCID:29837 SCORE: 0.00218737717770642
DOCNO: 15603864
AUTHOR: Christophe Libeer C
AUTHOR: Eric Verbeken E
AUTHOR: Walter De Wever W
AUTHOR: Johan Vansteenkiste J
AUTHOR: Kristiaan Nackaerts K
AFFILIATION: Department of Pulmonology, Respiratory Oncology Unit, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, B-3000 Leuven, Belgium.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Lung cancer (Amsterdam, Netherlands)
COUNTRY: Ireland
TITLE: Mediastinal emphysema and small cell lung cancer (SCLC): a case-report.
PUBDATE: 20050101
We present a case of a 59-year-old man with small cell lung cancer (SCLC) who developed heavy thoracic pain because of spontaneous mediastinal emphysema. Autopsy documented a mucosal lesion in the posterior tracheal wall with air leak towards the mediastinum. The occurrence of spontaneous mediastinal emphysema in patients with small cell lung cancer has rarely been described in the literature.


10. DOCID:29398 SCORE: 0.00218736667674352
DOCNO: 15203567
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: blood
QUALIFIER: blood
QUALIFIER: enzymology
QUALIFIER: blood
AUTHOR: Yves Denizot Y
AUTHOR: Véronique Truffinet V
AUTHOR: Stéphane Bouvier S
AUTHOR: Alain Gainant A
AUTHOR: Pierre Cubertafond P
AUTHOR: Muriel Mathonnet M
AFFILIATION: Laboratoire d'immunologie, Faculté de Médecine, UMR CNRS 6101, 2 rue Dr. Marcland, Limoges, France. yves.denizot@unilim.fr
PUBTYPE: Journal Article
JOURNALTITLE: Mediators of inflammation.
COUNTRY: England
TITLE: Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
PUBDATE: 20040201
This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.


11. DOCID:30835 SCORE: 0.00214416422455259
DOCNO: 15003201
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: Valerie Speirs V
AUTHOR: Pauline J Carder PJ
AUTHOR: Sally Lane S
AUTHOR: David Dodwell D
AUTHOR: Mark R J Lansdown MR
AUTHOR: Andrew M Hanby AM
AFFILIATION: Molecular Medicine Unit, University of Leeds, Leeds, UK. v.speors@leeds.ac.uk
PUBTYPE: Historical Article
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The lancet oncology.
COUNTRY: England
TITLE: Oestrogen receptor beta: what it means for patients with breast cancer.
PUBDATE: 20040301
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.


12. DOCID:31558 SCORE: 0.00210181222846618
DOCNO: 12522757
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Ureaplasma urealyticum
QUALIFIER: complications
QUALIFIER: microbiology
AUTHOR: Steven C Buckingham SC
AUTHOR: Dennis T Crouse DT
AUTHOR: Katherine M Knapp KM
AUTHOR: Christian C Patrick CC
AFFILIATION: Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA. sbuckingham@utmem.edu
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
COUNTRY: United States
TITLE: Pneumonitis associated with Ureaplasma urealyticum in children with cancer.
PUBDATE: 20030101
We describe 3 pediatric patients with cancer who had clinical and radiographic evidence of pneumonitis and for whom cultures of bronchoalveolar lavage fluid specimens yielded Ureaplasma urealyticum. Two of the patients died; for the surviving patient, clinical improvement coincided temporally with administration of erythromycin. Immunocompromised patients with pneumonitis of unclear etiology should have respiratory secretions cultured for mycoplasmas and should receive empiric therapy that includes a macrolide antibiotic.


13. DOCID:30167 SCORE: 0.00197360221541005
DOCNO: 15280663
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: Marina Melixetian M
AUTHOR: Kristian Helin K
AFFILIATION: European Institute of Oncology, Department of Experimental Oncology, Milan, Italy.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cell cycle (Georgetown, Tex.)
COUNTRY: United States
TITLE: Geminin: a major DNA replication safeguard in higher eukaryotes.
PUBDATE: 20040801
Eukaryotes have evolved multiple mechanisms to restrict DNA replication to once per cell cycle. These mechanisms prevent relicensing of origins of replication after initiation of DNA replication in S phase until the end of mitosis. Most of our knowledge of mechanisms controlling prereplication complex (preRC) formation are based on studies from yeast and Xenopus, while much less is known for mammalian cells. Here we discuss our recent data demonstrating that Geminin is required for preventing rereplication in human normal and cancer cells.


14. DOCID:31165 SCORE: 0.0019296142594135
DOCNO: 16167810
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Pneumonectomy
QUALIFIER: radiotherapy
QUALIFIER: secondary
QUALIFIER: secondary
QUALIFIER: pathology
AUTHOR: S Ohi S
AUTHOR: K Matsushita K
AUTHOR: H Toyoda H
AUTHOR: H Neyatani H
AUTHOR: K Suzuki K
AUTHOR: T Kazui T
AFFILIATION: Department of Tuhoracic Surgery, Iwata City Hospital, Iwata, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Kyobu geka. The Japanese journal of thoracic surgery.
COUNTRY: Japan
TITLE: [Non-small cell lung cancer simultaneously metastatic to the brain treated by lobectomy and stereotactic irradiation]
PUBDATE: 20050901
We performed left upper lobectomy in 64-year-old man with non-small cell lung cancer (NSCLC) simultaneously metastatic to the brain. He was treated by stereotactic irradiation (STI) 2 months later after lobectomy. He has been doing well now without recurrence for 5 years after the operation. We think that STI and radical lobectomy are good alternatives for patients with NSCLC metastatic to the brain.